Last reviewed · How we verify

budesonide plus formoterol combination — Competitive Intelligence Brief

budesonide plus formoterol combination (budesonide plus formoterol combination) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Corticosteroid and long-acting beta2-adrenergic receptor agonist combination. Area: Respiratory.

phase 3 Corticosteroid and long-acting beta2-adrenergic receptor agonist combination Beta2-adrenergic receptor Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

budesonide plus formoterol combination (budesonide plus formoterol combination) — Chiesi Farmaceutici S.p.A.. Budesonide is a corticosteroid that reduces inflammation, while formoterol is a long-acting beta2-adrenergic receptor agonist that relaxes airway muscles.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
budesonide plus formoterol combination TARGET budesonide plus formoterol combination Chiesi Farmaceutici S.p.A. phase 3 Corticosteroid and long-acting beta2-adrenergic receptor agonist combination Beta2-adrenergic receptor
Salmeterol 50 mcg via DISKUS Salmeterol 50 mcg via DISKUS GlaxoSmithKline marketed Long-acting beta2-adrenergic agonist (LABA) Beta2-adrenergic receptors
Symbicort Turbohaler Symbicort Turbohaler Pearl Therapeutics, Inc. phase 3 Corticosteroid and long-acting beta2-adrenergic receptor agonist combination Beta2-adrenergic receptor
Seretide Evohaler Seretide Evohaler FLUIDDA nv phase 3 Corticosteroid and long-acting beta2-adrenergic receptor agonist combination Beta2-adrenergic receptor
Symbicort TBH - Turbuhaler Symbicort TBH - Turbuhaler AstraZeneca phase 3 Corticosteroid and long-acting beta2-adrenergic receptor agonist combination Beta2-adrenergic receptor
Salmeterol/Fluticasone propionate combination product Salmeterol/Fluticasone propionate combination product GlaxoSmithKline phase 3 Long-acting beta2-adrenergic receptor agonist/inhaled corticosteroid combination Beta2-adrenergic receptor
Symbicort® Turbohaler® Inhalation Powder Symbicort® Turbohaler® Inhalation Powder Pearl Therapeutics, Inc. phase 3 Inhaled corticosteroid/long-acting beta2-adrenergic agonist Beta2-adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Corticosteroid and long-acting beta2-adrenergic receptor agonist combination class)

  1. AstraZeneca · 1 drug in this class
  2. Chiesi Farmaceutici S.p.A. · 1 drug in this class
  3. FLUIDDA nv · 1 drug in this class
  4. Pearl Therapeutics, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). budesonide plus formoterol combination — Competitive Intelligence Brief. https://druglandscape.com/ci/budesonide-plus-formoterol-combination. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: